

ANNUAL FINANCIAL STATEMENTS

82

**BALANCE SHEET AS OF
31 DECEMBER 2024**

84

**STATEMENT OF PROFIT
AND LOSS FOR THE 2024
FINANCIAL YEAR**

86

**NOTES TO THE FINANCIAL
STATEMENTS FOR THE 2024
FINANCIAL YEAR**

114

**STATEMENT OF CHANGES
IN FIXED ASSETS AS OF
31 DECEMBER 2024**

116

INDEPENDENT AUDITORS REPORT


Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

BALANCE SHEET AS OF 31 DECEMBER 2024

ASSETS	EUR	EUR	EUR	31.12.2024 EUR	31.12.2023 TEUR
A. Fixed assets					
I. Intangible assets					
1. Purchased concessions, industrial property rights and similar rights and assets, as well as licences to such rights and assets		6,495,576.81			7,390
2. Prepayments made		1,514,016.93			911
			8,009,593.74		8,301
II. Tangible fixed assets					
1. Land, rights equivalent to land, and buildings including buildings on third-party land		1,381,071,339.91			1,299,418
2. Technical plant and machinery		457,164,150.50			465,432
3. Other plant, operating and office equipment		179,772,612.78			174,435
4. Prepayments made and plant under construction		291,677,290.30			357,523
			2,309,685,393.49		2,296,808
III. Financial assets					
1. Shares in affiliated companies		608,200.00			608
2. Participations		654,746.09			667
3. Investment securities		399,577,192.86			408,899
4. Other loans and shares		3,433,453.55			2,938
			404,273,592.50		413,112
				2,721,968,579.73	2,718,221
B. Current assets					
I. Inventories					
1. Research materials		11,275,977.00			11,446
2. Other materials		630,018.38			879
3. Work-in-progress		390.28			1
			11,906,385.66		12,326
II. Receivables and other assets					
1. Trade receivables		9,994,601.10			12,132
2. Receivables due from funding providers					
a) from institutional funding	210,765,769.90				252,377
b) from project funding	33,778,289.44				32,816
c) from compensation claims	920,591,418.22				898,593
		1,165,135,477.56			1,183,786
3. Receivables due from affiliated companies		7,317,944.38			5,821
4. Receivables due from companies in which an equity interest is held		4,583,699.66			11,641
5. Other assets		13,514,319.75			14,549
			1,200,546,042.45		1,227,929
III. Securities					
Other securities			703,040.35		5,591
IV. Cash in hand, bank balances and cheques			181,014,798.02		198,299
				1,394,170,266.48	1,444,145
C. Deferred expenses and accrued income				48,497,281.16	46,433
TOTAL				4,164,636,127.37	4,208,799
<i>for information purposes:</i>					
Trust assets				209,614,836.12	128,350

EQUITY AND LIABILITIES

	EUR	EUR	EUR	31.12.2024 EUR	31.12.2023 TEUR
A. Equity					
I. Association capital			468,768,998.71		487,201
II. Reserves for statutory purposes			26,848,552.01		27,415
III. Result carried forward			743,009.86		1,025
				496,360,560.58	515,641
B. Extraordinary item					
1. From subsidies for fixed assets			2,230,904,066.50		2,216,555
2. From subsidies for current assets			109,759,217.49		111,111
				2,340,663,283.99	2,327,666
C. Provisions					
1. Provisions for pensions and similar obligations			798,852,290.00		786,075
2. Tax provisions			0.00		86
3. Other provisions			119,212,530.50		109,539
				918,064,820.50	895,700
D. Liabilities					
1. Bank borrowings			482,457.05		499
2. Trade payables			49,181,049.54		70,801
3. Liabilities to funding providers					
a) from institutional funding		206,698,264.55			227,589
b) from project funding		121,847,863.99			139,402
			328,546,128.54		366,991
4. Liabilities due to affiliated companies			4,857,288.79		9,093
5. Liabilities due to companies in which an equity interest is held			122,973.02		98
6. Other liabilities			25,746,567.97		21,571
– of which from tax:		12,494,203.18			
		(31.12.2023: 11,659,786.81)			
– of which as part of social security:		2,987,464.35			
		(31.12.2023: 2,947,182.56)			
				408,936,464.91	469,053
E. Deferred income and accrued expenses				610,997.39	739

**TOTAL****4,164,636,127.37****4,208,799**

for information purposes:

Trust assets

209,614,836.12

128,350

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

STATEMENT OF PROFIT AND LOSS FOR THE 2024 FINANCIAL YEAR

	EUR	EUR	2024 EUR	Previous year TEUR
1. Subsidies from institutional funding				
1.1 Basic funding		2,127,142,417.70		2,064,856
1.2 Partial special funding		17,402,000.00		16,450
1.3 Special funding		6,084,518.67		16,725
1.4 Other partial special funding		2,242,503.00		2,132
			2,152,871,439.37	2,100,163
2. Changes in receivables due from funding providers deriving from compensation claims (increase/(-) decrease)			21,998,548.83	53,828
3. Own revenues and other income				
3.1 Income from research and development and from utilization of research facilities		6,117,510.38		4,336
3.2 Income from licence and know-how agreements		11,258,172.12		8,240
3.3 Income from infrastructure services and sales of materials		25,707,240.32		26,847
3.4 Rental and lease income		15,364,781.24		15,669
3.5 Income from fixed asset disposals		8,493,243.51		1,269
3.6 Increase /(-) decrease in work-in-progress		0.00		0
3.7 Other work performed by the enterprise and capitalized		3,830,791.88		5,988
3.8 Financial income, income from participating interests, interest income		6,611,365.14		4,990
3.9 Other operating income		358,978,924.79		354,071
			436,362,029.38	421,410
4. Subsidies from project funds			310,289,372.36	284,137
5. Income from release of extraordinary items (loan repayment)			58,864.05	68
6. Personnel expenses				
6.1 Wages and salaries		1,128,453,478.93		1,058,123
6.2 Social security contributions and expenses for pensions and benefits		319,029,319.17		320,642
– of which for pensions:		103,917,990.57 (previous year: 120,006,323.80)		
			1,447,482,798.10	1,378,765
carried forward			1,474,097,455.89	1,480,841

	EUR	EUR	2024 EUR	Previous year TEUR
carried forward			1,474,097,455.89	1,480,841
7. Costs of materials				
7.1 Expenses for raw materials, consumables and supplies, and for purchased goods		235,740,060.92		230,339
7.2 Expenses for purchased services		14,484,124.20		11,862
			250,224,185.12	242,201
8. Change in the extraordinary item for current assets (increase/(-) decrease)			-905,205.82	16,354
9. Depreciation and amortization of intangible and tangible fixed assets				
9.1 Depreciation and amortization of intangible and tangible fixed assets		324,478,470.29		320,882
9.2 Income from release due to depreciation and amortization of extraordinary items for intangible and tangible fixed assets		322,173,901.17		318,503
			2,304,569.12	2,379
10. Depreciation and amortization on securities under current assets				
10.1 Depreciation and amortization on securities under current assets		1,794.90		525
10.2 Income from release due to depreciation and amortization of extraordinary items for securities of current assets		0.00		370
			1,794.90	155
11. Other expenses				
11.1 Interest and similar expenses		14,160,165.58		12,460
– of which from the reversal of discounts to provisions:	14,157,641.90 (previous year: 12,457,173.67)			
11.2 Other operating expenses		836,589,612.85		804,604
			850,749,778.43	817,064
12. Transfers and subsidies granted			50,271,450.31	45,375
13. Expenses from addition to the extraordinary item (subsidized investments)				
13.1 to finance intangible and tangible fixed assets		340,539,334.95		372,555
13.2 to finance financial assets and shares in spin-offs		192,201.25		108
			340,731,536.20	372,663
14. Annual result			-19,280,652.37	-15,350
15. Result carried forward from the previous year			1,025,457.25	1,431
16. Withdrawals from the association capital			19,344,541.70	20,903
17. Withdrawals from reserves for statutory purposes			2,499,835.36	3,652
18. Allocations to association capital			-912,450.67	-7,622
19. Allocations to reserves for statutory purposes			-1,933,721.41	-1,989
20. Result carried forward			743,009.86	1,025

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

NOTES TO THE FINANCIAL STATEMENTS FOR THE 2024 FINANCIAL YEAR

of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin
Register of Societies No. VR 13378 B, Berlin-Charlottenburg District Court


1. General information on the Annual Financial Statements

The annual financial statements of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (hereafter "MPG") were prepared in analogous application of the regulations of the Third Book of the German Commercial Code (HGB) for large corporations with due consideration given to association law.

The annual financial statements of MPG include the following accounting entities:

- Legally dependent Institutes and research units as well as central institutions
- "Assets not publicly funded" (hereafter NÖV)
- Operations pursuant to § 26 of the Federal Budget Ordinance (BHO) (including the MPI for Psychiatry)
- Max Planck Institute for Plasma Physics (hereafter IPP)¹

Together with the legally independent Max Planck Institutes (the Max-Planck-Institut für Nachhaltige Materialien Gesellschaft mit beschränkter Haftung and the Max-Planck-Institut für Kohlenforschung (rechtsfähige Stiftung)), the MPG excluding IPP forms a consortium of applicants which is the recipient of joint institutional funding from the federal administration and federal states. The annual financial statements of the legally independent Institutes are not included in the annual financial statements of the MPG.



The "assets not publicly funded" represent assets belonging to the MPG made up of private third-party funds which are managed with due regard for intended purpose, tax regulations and public funding law. The MPG generates income from these assets, which is used for the promotion of research. In the explanations on individual items on the assets side of the balance sheet, the share of assets not publicly funded is identified by applying a further breakdown of figures.

¹Das IPP gehört seit 1.1.2021 zur Antragsgemeinschaft der MPG. Bis zum 31.12.2020 war das IPP assoziiertes Mitglied der Helmholtz-Gemeinschaft.

Advantage was taken of the options afforded under §265 paras. 5 to 7 HGB in order to reflect the particularities specific to the sector and legal form of MPG as a research facility, and to ensure a clear, transparent presentation. On the one hand, the designation and structure of the items of the balance sheet and of the statement of profit and loss were adjusted, and on the other, items in the profit and loss account were combined. In accordance with the budget of the MPG, scholarships for supported junior personnel are shown under personnel expenses.

2. Accounting Policies

Intangible and tangible fixed assets are measured at their costs of purchasing or manufacturing on the date of addition. For subsequent valuation, they are amortized and depreciated exclusively applying the straight-line method. For this purpose, the MPG applies a generalized useful life specific to asset class.

Low-value assets with costs of purchasing and manufacturing up to EUR 800 (net) inclusive are fully expensed in special accounts in the year of purchase.

Financial assets are recognized at purchase cost. Financial assets are written down to the lower of cost or fair value given prospectively permanent impairment.

The research materials shown under inventories and other materials are recognized at the lower of cost or fair value.

Work-in-progress includes work conducted by IPP – measured on the basis of unit costings – which, as well as directly attributable costs of materials, wage costs and special costs, also including appropriate portions of production and materials overheads as well as the asset erosion of the utilized fixed assets.

Receivables and other assets are recognized at the lower of nominal or fair value. No generalized valuation allowances have been applied due to the minor portfolio of receivables, which is generally to be regarded as collectible.

Liquid funds are measured at nominal value.

Current bank balances denominated in foreign currencies were translated at the spot mid exchange rate on the balance sheet date in accordance with §256a HGB.

Accruals and deferrals are formed in accordance with the principles of periodic allocation.

Equity is reported based on the IDW accounting standard "Accounting for associations" (IDW RS HFA 14).

The MPG receives funding from the public sector and other third parties. Where these have been used for the purchase or production of fixed assets requiring capitalization, they have been recognized as liabilities in the form of an extraordinary item from subsidies for fixed assets, and are not offset with costs of purchasing or manufacturing (gross method). This does not apply to assets of the NÖV.

Similarly, the extraordinary item from subsidies for current assets reflects the current assets financed through institutional or project funding.

Provisions are formed for all identifiable risks and contingent obligations, taking due account of the probable utilization at the settlement amount required on the basis of prudent commercial judgement. Future increases in prices and costs are taken into account if sufficient objective indications exist that they will occur. Provisions are discounted in accordance with §253 para. 2 HGB if their residual term is more than one year, in other words, applying the average market interest rate corresponding to the residual term, derived in the case of pension provisions over the past ten financial years, and in the case of other provisions from the past seven financial years. Income or expenses resulting from changes in the discount rate, or the interest effects of a

change in the estimate of the residual term, are shown in personnel expenses or in other operating expenses, depending on the provision type.

Pension provisions have been calculated based on an independent actuarial report in accordance with the accrued funding method, taking into account the 2018 G Mortality Tables of Prof. Dr. Heubeck. A trend of 2.00% (previous year 2.00%) was assumed for both salaries and pensions. The average market interest rate for the past ten years of 1.90% (previous year 1.83%) was applied for the discounting for a generalized residual term of 15 years. The discounting applying the average market interest rate for the past ten years generates a difference of EUR -6,142,480 (previous year EUR 6,793,114) compared with discounting applying the average market rate for the past seven years (1.96%).

Provisions for aid obligations have been calculated based on an independent actuarial report in accordance with the accrued funding method, taking into account the probability tables (average insurance payout statistics [Kopfschadenstatistiken]) in private health insurance for 2023², as published by the German Federal Financial Supervisory Authority (BaFin), as well as the 2018 G Mortality Tables of Prof. Dr. Heubeck. This entailed taking as a basis an average market interest rate for the past seven years of 1.96% (previous year 1.74%) for a generalized residual term of 15 years and a benefit trend of 2.00% (previous year 2.00%).

The partial retirement provision was determined by means of an independent actuarial report taking into account the 2018 G Mortality Tables of Prof. Dr. Heubeck. As well as settlement arrears, the calculation includes the complete amounts above the current salary in existing partial retirement arrangements. The calculation was based on an average market interest rate from the last seven years of 1.49% corresponding to the residual term (previous year 1.03%), 1.50% for IPP (previous year 0.99%) as well as a salary trend of 3.30% (previous year 3.30%).

The anniversary obligation provision was determined by means of an independent actuarial report based on the projected unit credit method taking into account the 2018 Mortality Tables of Prof. Dr. Heubeck, an actuarial interest rate of 1.96% (previous year 1.74%) for a generalized residual term of 15 years, and a salary trend of 2.00% (previous year 2.00%).

Liabilities are recognized at their settlement amount.

Receivables and liabilities denominated in foreign currencies are translated on the balance sheet date at the spot mid exchange rate.

Trust assets essentially comprise trust-administered EU project funds. They are matched by corresponding trust liabilities.

The statement of profit and loss is complemented by a statement showing the application of results.

²The calculation is based on the statistics for 2023 (published on 17 December 2024).

3. Explanations and notes to the balance sheet

3.1 Fixed assets

Changes in individual items of fixed assets are shown in the annex to the notes to the financial statements in the statement of changes in fixed assets.

Intangible assets

	31.12.2024 TEUR	<i>of which NÖV</i>	31.12.2023 TEUR
INTANGIBLE ASSETS			
Purchased concessions, industrial property rights and similar rights and assets, as well as licences to such rights and assets	6,496	0	7,390
Prepayments made	1,514	0	911
TOTAL	8,010	0	8,301

Intangible assets essentially comprise software licences.

The MPG does not make use of the capitalization option for internally generated intangible assets pursuant to §248 para. 2 HGB.

Tangible fixed assets

	31.12.2024 TEUR	<i>of which NÖV</i>	31.12.2023 TEUR
TANGIBLE FIXED ASSETS			
Land, rights equivalent to land, and buildings including buildings on third-party land	1,381,071	85,663	1,299,418
Technical plant and machinery	457,164	0	465,432
Other plant, operating and office equipment	179,773	991	174,435
Prepayments made and plant under construction	291,677	70	357,523
TOTAL	2,309,685	86,724	2,296,808

The following large-scale construction projects were, among other items, capitalized in the reporting year after completion:

	TEUR
MPI for the Science of Light, Erlangen, New building for the Center for Physics and Medicine	58,984
MPI for Chemical Energy, Mülheim, partial new institute building	49,368

The item **technical plant and machinery** comprises essentially the scientific equipment and devices as well as operating facilities (mainly fixed installations in laboratories, animal facilities and greenhouses), produced as part of the construction projects.

The item **other plant, operating and office equipment** is comprised as follows on the balance sheet date:

	31.12.2024 TEUR	31.12.2023 TEUR
Other plant, operating and office equipment		
Facility and IT equipment	142,867	136,643
Libraries	35,593	36,543
Vehicles	1,313	1,249
TOTAL	179,773	174,435

The decrease in **prepayments made and plant under construction** is mainly due to the capitalization of construction measures after completion.

Financial assets

	31.12.2024 TEUR	of which NÖV	31.12.2023 TEUR
FINANCIAL ASSETS			
Shares in affiliated companies	608	526	608
Participations	655	555	667
Investment securities	399,577	399,577	408,899
Other loans and shares	3,434	3,126	2,938
TOTAL	404,274	403,784	413,112

There were no indications of prospectively permanent impairment as of the balance sheet date.

The reported **participations** serve the MPG as part of its statutory purpose to establish long-term science-driven cooperation.

The **securities** held as fixed assets are exclusively attributable to the NÖV.

Other loans and shares contain loans for housebuilding funding (family home loans) amounting to TEUR 3,416 as well as other loans (TEUR 18).

An overview of shareholdings can be found in note 5 Other disclosures of these notes to the financial statements.

3.2 Current assets

Inventories

Inventories comprise assets which are not serving operations on a continuing basis and are purchased for consumption. As the MPG conducts basic research, instead of the raw materials, consumables and supplies closely associated with production manufacturing, the materials required for research are reported and divided as follows within inventories:

	31.12.2024 TEUR	of which NÖV	31.12.2023 TEUR
INVENTORIES			
Research materials	11,276	0	11,446
Other materials	630	37	879
Work-in-progress	0	0	1
TOTAL	11,906	37	12,326

Receivables and other assets

	31.12.2024 TEUR	of which NÖV	31.12.2023 TEUR
RECEIVABLES AND OTHER ASSETS			
Trade receivables	9,995	25	12,132
Receivables due from funding providers	1,165,135	0	1,183,786
Receivables due from affiliated companies	7,318	1	5,821
Receivables due from companies in which an equity interest is held	4,584	0	11,641
Other assets	13,514	5,075	14,549
TOTAL	1,200,546	5,101	1,227,929

Trade receivables relate in an amount of TEUR 7,694 (previous year TEUR 8,288) to receivables from hospital services of the MPI for Psychiatry.

	31.12.2024 TEUR	31.12.2023 TEUR
Receivables due from funding providers		
from institutional funding	210,766	252,377
from project funding	33,778	32,816
from compensation claims	920,591	898,593
TOTAL	1,165,135	1,183,786

Receivables due from funding providers from institutional funding essentially represent receivables for approved funding in the reporting year whose multi-year availability is established by the budget instrument of funds managed under own responsibility (Selbstbewirtschaftung). This position contains funds managed under own responsibility for the federal administration and its federal states, in the amount of TEUR 197,005, of which TEUR 44,200 for IPP (previous year TEUR 235,475, of which TEUR 46,000 for IPP). Also shown here are claims to additional payments from federal states resulting from the final calculation by the MPG of fund distribution, which in principle are to be paid in the third year following billing (TEUR 9,068); of this amount, TEUR 5,107 has a residual term of over one year.

Receivables due from funding providers from project funding include project funding expenditure covered by funding approval letters from third-party funding bodies if the third-party funds have not yet been received.

Receivables due from funding providers from compensation claims form the counterpart, in principle, to obligations entered into on the basis of a funding relationship and not covered by funds in the current financial year (No. 4(2) of the Management Principles for the MPG (BewGr-MPG)). They are comprised as follows as on the reporting date:

	TEUR
MPG excluding IPP	882,462
IPP	38,129

Of the compensation claims, a total of TEUR 810,704 (previous year TEUR 800,202) have a residual term of over one year.

Receivables due from affiliated companies relate mainly to receivables due from Max-Planck-Innovation GmbH deriving from licence income.

Receivables due from companies in which an equity interest is held relate to receivables from MPDL Services gGmbH.

As of the balance sheet date, **other assets** include:

	TEUR
VAT receivables due from tax authorities	2,917
Claims from legacies (NÖV)	1,884
Receivables from investment securities (NÖV)	1,829
Shares in spin-offs held-for-disposal	942

Spin-offs are companies established to convert a technology or scientific know-how developed at a Max Planck Institute into products and services, among other objectives. Equity interests in spin-offs are held on the basis of guidelines for research facilities to participate in spin-offs for the purpose of the transfer of knowledge and technology published by the Federal Ministry of Education and Research.

Securities

	31.12.2024 TEUR	of which NÖV	31.12.2023 TEUR
SECURITIES			
Other securities	703	703	5,591

The other securities are mainly components from inheritances in the NÖV that are earmarked for sale.

Cash in hand, bank balances and cheques

	31.12.2024 TEUR	of which NÖV	31.12.2023 TEUR
Cash in hand, bank balances and cheques	181,015	3,844	198,299

As of the reporting date, the liquid funds position contains unutilized budget funds from institutional funding whose multi-year availability is established by other budget instruments outside of funds managed under own responsibility (Selbstbewirtschaftung), as well as funds from project funding which can also be transferred to the following year.

3.3 Deferred expenses and accrued income

	31.12.2024 TEUR	of which NÖV	31.12.2023 TEUR
Deferred expenses and accrued income	48,497	54	46,433

Deferred expenses and accrued income contain expenditure before the balance sheet date which will only be recognized after that date. This item mainly contains prepayments of licensing fees and usage fees for (online) media. Salary payments of TEUR 6,584 for January 2025 are included, which are due on 1 January 2025.

3.4 Trust assets

The trust assets include TEUR 208,775 of trust-administered EU project funds, of which TEUR 101,431 are attributable to IPP.

3.5 Equity

	31.12.2024 TEUR	31.12.2023 TEUR
EQUITY		
Association capital	468,769	487,201
Reserves for statutory purposes	26,849	27,415
Result carried forward	743	1,025
TOTAL	496,361	515,641

Equity is entirely accounted for by NÖV. Equity is reported with due consideration given to funding provider requirements and reflecting tax law regulations. Regarding the reserves, the specifications contained in the regulations of the German Fiscal Code (AO) have been implemented. The net loss for the financial year (TEUR 19,281), which is mainly due to the financing of the MPI for the Neurobiology of Behavior – caesar in the form of a consumption foundation, had the effect of reducing equity.

Apart from NÖV, the annual financial statements of the MPG close without net profit or net loss for the year.

3.6 Extraordinary item

The extraordinary item is comprised as follows:

	31.12.2024 TEUR	31.12.2023 TEUR
EXTRAORDINARY ITEM		
from subsidies for fixed assets	2,230,904	2,216,555
from subsidies for current assets	109,759	111,111
TOTAL	2,340,663	2,327,666

The **extraordinary item from subsidies for fixed assets** reflects the fixed assets funded by public sector subsidies and subsidies from other third parties. Accordingly, no extraordinary item was formed for NÖV fixed assets and for an inheritable building right

at the MPI for Psychiatry (TEUR 557), which is matched by a long-term liability. This results in the following table of extraordinary items and fixed assets as of the closing date:

	Fixed assets covered by extraordinary items	Fixed assets not covered by extraordinary items		Total fixed assets
	TEUR	NÖV TEUR	MPI for Psychiatry TEUR	TEUR
Intangible assets	8,010	0	0	8,010
Tangible fixed assets	2,222,404	86,724	557	2,309,685
Financial assets	490	403,784	0	404,274
TOTAL	2,230,904	490,508	557	2,721,969

The **extraordinary item from subsidies for current assets** reflects the current assets financed through institutional or project funding.

3.7 Provisions

Provisions for pensions and similar obligations are comprised as follows:

	01.01.2024 TEUR	Consumption TEUR	Release TEUR	Reversal of discount TEUR	Addition TEUR	31.12.2024 TEUR
Pension obligations	647,788	21,057	12,384	11,662	61,927	687,936
Aid obligations	138,287	3,638	26,108	2,375	0	110,916
TOTAL	786,075	24,695	38,492	14,037	61,927	798,852

Provisions for pensions and similar obligations are formed for benefit claims and entitlements for aid resulting from employment contracts similar to civil service contracts which may be concluded under the conditions pertaining to the Annex to No. 8(1) Bew-Gr-MPG. A total of 1,313 (previous year 1,316) entitled persons, of whom 660 active (previous year 655), are included in the provision for pension obligations as of the reporting date, and a total of 944 (previous year 951) entitled persons, of whom 467 active (previous year 475), are included in the provision for aid obligations. The interest expense shown derives from reversing the discount to the obligation at the beginning of the period applying the interest rate defined at this time, taking into consideration the interest portion of the pensions or aid paid to the beneficiaries in the reporting year.

The difference between discounting applying the average market interest rate for the past ten years and discounting applying the average market interest rate for the past seven years amounts to TEUR –6,142 (previous year TEUR 6,793) for the provisions for pension obligations as of the reporting date.

The **tax provisions** amount to TEUR 0 as of the balance sheet date (previous year TEUR 86).

Other provisions are comprised as follows:

	01.01.2024 TEUR	Consumption TEUR	Release TEUR	Reversal of discount TEUR	Addition TEUR	31.12.2024 TEUR
Remaining vacation	56,842	56,842	0	0	62,708	62,708
Invoices outstanding	18,289	18,233	56	0	24,946	24,946
Partial retirement	8,279	4,759	0	58	2,229	5,807
Overtime/time credits	8,805	4,690	0	0	5,490	9,605
Archiving costs	3,406	12	0	0	146	3,540
Service anniversaries	2,440	205	0	35	235	2,505
Legal costs	1,791	96	114	0	19	1,600
Travel costs not yet invoiced	2,778	2,778	0	0	2,828	2,828
Miscellaneous other provisions	6,909	2,527	841	28	2,105	5,674
TOTAL	109,539	90,142	1,011	121	100,706	119,213

Besides short-term flexi-time credits, provisions for overtime/time credits also include longer-term working time accounts in an amount of TEUR 4,189.

3.8 Liabilities

	31.12.2024 TEUR	31.12.2023 TEUR
LIABILITIES		
Bank borrowings	482	499
Trade payables	49,181	70,801
Liabilities to funding providers	328,546	366,991
Liabilities due to affiliated companies	4,857	9,093
Liabilities due to companies in which an equity interest is held	123	98
Other liabilities	25,747	21,571
TOTAL	408,936	469,053

Bank borrowings relate entirely to NÖV.

Trade payables mainly contain typical liabilities from supplies and services. They also include warranty retentions of TEUR 586 (previous year TEUR 624).

	31.12.2024 TEUR	31.12.2023 TEUR
Liabilities to funding providers		
from institutional funding	206,698	227,589
from project funding	121,848	139,402
TOTAL	328,546	366,991

Pursuant to No. 5 of the Management Principles for the MPG (BewGr-MPG), the multi-year availability of funding from institutional funding providers can be established by means of funds managed under own responsibility (Selbstbewirtschaftung) or by another budget instrument. These multi-year available funds are shown on the balance sheet as **liabilities to funding providers from institutional funding**. The balance of approved subsidies, own revenues and other income as well as expenditure in the reporting year is shown.

Also shown here are TEUR 15,512 of reimbursement claims of federal states resulting from the MPG's final calculation of fund distribution which in principle are to be paid in the third year following billing; TEUR 7,803 of this amount has a residual term of over one year.

Liabilities to funding providers from project funding essentially contain the funds available for the following year as the balance of third-party funding subsidies received, own revenues and other income, and expenses in the reporting year.

Liabilities due to affiliated companies mainly relate to the Max-Planck-Institut für Nachhaltige Materialien GmbH in the framework of funding not yet called off as part of the consortium of applicants in 2024.

Other liabilities contain liabilities towards tax authorities resulting from income tax in the amount of TEUR 12,493 as of the balance sheet date.

The following **statement of liabilities** shows the residual terms of individual liability items (previous-year data in parentheses):

	31.12.2024 TEUR	Residual term		
		up to 1 year TEUR	1 to 5 years TEUR	more than 5 years TEUR
STATEMENT OF LIABILITIES				
Bank borrowings	482 (499)	17 (17)	69 (68)	396 (414)
Trade payables	49,181 (70,801)	49,181 (70,801)	0 (0)	0 (0)
Liabilities to funding providers	328,546 (366,991)	320,743 (359,282)	7,803 (7,709)	0 (0)
Liabilities due to affiliated companies	4,857 (9,093)	4,857 (9,093)	0 (0)	0 (0)
Liabilities due to companies in which an equity interest is held	123 (98)	123 (98)	0 (0)	0 (0)
Other liabilities	25,747 (21,571)	25,541 (21,297)	206 (274)	0 (0)
TOTAL	408,936 (469,053)	400,462 (460,588)	8,078 (8,051)	396 (414)

The liabilities are not secured through rights of lien or similar rights.

3.9 Deferred income and accrued expenses

	31.12.2024 TEUR	31.12.2023 TEUR
Deferred income and accrued expenses	611	739

Deferred income and accrued expenses contains revenues received before the balance sheet date which will only be recognized in profit or loss after that date.

4. Explanations to the statement of profit and loss

Subsidies from institutional funding

The subsidies from institutional funding (TEUR 2,152,871, previous year TEUR 2,100,163) are comprised as follows in the reporting year:

	2024 MPG excl. IPP TEUR	2024 IPP TEUR	2024 MPG TEUR	2023 MPG TEUR
SUBSIDIES FROM INSTITUTIONAL FUNDING				
Basic funding	1,998,394	128,748	2,127,142	2,064,856
<i>of which from federal government</i>	1,103,803	116,308	1,220,111	1,205,137
<i>of which from federal states</i>	894,591	12,440	907,031	859,719
Partial special funding	17,402	0	17,402	16,450
<i>of which from federal government</i>	0	0	0	0
<i>of which from federal states</i>	17,402	0	17,402	16,450
Special funding	6,085	0	6,085	16,725
<i>of which from federal government</i>	0	0	0	11,817
<i>of which from federal states</i>	6,085	0	6,085	4,908
Other partial special funding	2,242	0	2,242	2,132
TOTAL	2,024,123	128,748	2,152,871	2,100,163

The federal government and the federal states provide on a 50:50 basis the financial funding in the **basic funding** of the MPG excluding IPP. For IPP, the ratio of basic funding is 90:10. In accordance with the agreement of the Joint Initiative for Research and Innovation IV, a budget growth of 3% was granted by the funding providers.

As **partial special funding** and **special funding** from the federal states, funds amounting to TEUR 17,402 and TEUR 6,085 were received in 2024.

Other partial special funding relates to a subsidy from the Netherlands for the MPI for Psycholinguistics, Nijmegen.

Changes in receivables due from funding providers deriving from compensation claims

The change in receivables due from funding providers deriving from compensation claims of TEUR 21,999 (previous year TEUR 53,828) is comprised as follows:

	2024 TEUR	2023 TEUR
MPG excluding IPP	20,755	48,498
IPP	1,244	5,330

Own revenues and other income

Own revenues and other income (TEUR 436,362 previous year TEUR 421,410) are comprised as follows:

	2024 TEUR	2023 TEUR
OWN REVENUES AND OTHER INCOME		
Income from research and development, and from utilization of research facilities	6,118	4,336
Income from licence and know-how agreements	11,258	8,240
Income from infrastructure services and sales of materials	25,707	26,847
Rental and lease income	15,365	15,669
Income from fixed asset disposals	8,493	1,269
Increase/(-) decrease in work-in-progress	0	0
Other work performed by the enterprise and capitalized	3,831	5,988
Financial income, income from participating interests, interest income	6,611	4,990
Other operating income	358,979	354,071
<i>containing</i>		
<i>Income relating to another accounting period</i>	3,483	2,282
<i>Other income</i>	61,383	48,826
<i>Release of multi-year available funds</i>	294,113	302,963

Income from licence and know-how agreements originated from the utilization of the MPG's intangible invention assets by Max-Planck-Innovation GmbH and from the disposal of shares in technology transfer spin-offs. In addition to the income received up to the preparation of the financial statements, the income includes forecast income in the amount of TEUR 6,807 (previous year TEUR 5,762) that is attributable to the financial year but will only be received in the course of the following year.

Income from infrastructure services and sales of materials consists mainly of revenues generated by the MPI for Psychiatry from hospital services.

Rental and lease income results mainly from letting guest apartments and guest rooms. It also contains NÖV income (including the conference venues Schloss Ringberg and Harnack-Haus) in the amount of TEUR 5,167 (previous year TEUR 4,627).

Expenditure arising from the disposal of fixed assets (for subsidy-financed fixed assets) is offset by the same amount of income resulting from the release of the extraordinary item from subsidies for fixed assets, and is shown in **income from fixed asset disposals**.

Of the **other work performed by the enterprise and capitalized** an amount of TEUR 2,988 is attributable to the IPP (previous year: TEUR 4,172).

Financial income, income from participating interests, interest income contains income from securities recognized in NÖV, amounting to TEUR 3,618 (previous year TEUR 3,308).

Income relating to another accounting period includes income from subsequent capitalizations in an amount of TEUR 525.

Other income contains income from the release of provisions amounting to TEUR 39,513 (previous year TEUR 19,643).

Multi-year available funds from institutional funding as well as from project funding in the current year are expensed as a liability to funding providers, and released in the following year as income in the same amount. The **release of multi-year available funds** (from 2023) relates only to MPG excluding IPP, and is comprised as follows:

TEUR

Release of multi-year available funds	
Basic funding	185,673
Special funding	-127
Project funding	96,877
Undisbursed funds for operations pursuant to § 26 of the Federal Budget Ordinance (BHO) including MPI for Psychiatry	11,690
TOTAL	294,113

Subsidies from project funds

IPP accounts for TEUR 23,947 (previous year TEUR 20,008) of the TEUR 310,289 subsidies from project funds (previous year TEUR 284,137).

Income from the release of extraordinary items (loan repayment)

This item (TEUR 59, previous year TEUR 68) contains the income from the release of the extraordinary item from subsidies for fixed assets arising from redemption payment of family home loans.

Personnel expenses

Personnel expenses (TEUR 1,447,483, previous year TEUR 1,378,765) contain expenses for the support of junior scientists amounting to TEUR 399,636 (previous year TEUR 371,276). Scholarship holders account for TEUR 13,327 (previous year TEUR 14,504).

Social security contributions and expenses for pensions and benefits (TEUR 319,029, previous year TEUR 320,642) includes the balance from the addition to, and consumption of, provisions for pension obligations in an amount of TEUR 40,870 (previous year TEUR 60,457) and for aid obligations in an amount of TEUR -3,638 (previous year TEUR -1,635). Expenses for aid payments were incurred in a total of TEUR 5,388 (previous year TEUR 5,351) and for childcare costs in an amount of TEUR 1,857 (previous year TEUR 1,941).

Costs of materials

Expenses for raw materials, consumables and supplies, and for purchased goods (TEUR 235,740, previous year TEUR 230,339) mainly contain expenses for research materials of TEUR 105,199 (previous year TEUR 107,445) and expenses for power and water supplies amounting to TEUR 127,418 (previous year TEUR 119,623).

Expenses for purchased services of TEUR 14,484 (previous year TEUR 11,862) chiefly represent expenses for awarding external research contracts in the area of third-party funding.

Change in the extraordinary item for current assets

The decrease in the extraordinary item for current assets in an amount of TEUR 905 is composed of:

- the decrease in the extraordinary item recognized on the balance sheet for current assets (TEUR -1,352),
- plus the change to shares in spin-offs held for disposal (TEUR 447).

Depreciation and amortization of intangible and tangible fixed assets

Since fixed assets are shown by the gross method, which necessitates showing depreciation and amortization as an expense item in the statement of profit and loss, an amount corresponding to the depreciation and amortization (TEUR 324,479, previous year TEUR 320,882) is released from the extraordinary item of subsidies to fixed assets (TEUR 322,174, previous year TEUR 318,503) without affecting the annual result (for the subsidy-financed fixed assets). The difference corresponds to the depreciation and amortization of the fixed assets not covered by extraordinary items relating to NÖV and MPI for Psychiatry.

Depreciation and amortization on securities under current assets

Depreciation and amortization on securities under current assets amounted to TEUR 2 (previous year: TEUR 525) and were taken to the lower fair value as of the balance sheet date.

Other expenses

Interest and similar expenses (TEUR 14,160, previous year TEUR 12,460) consist almost entirely of interest expenses arising from the reversal of discounts to provisions (TEUR 14,158, previous year TEUR 12,457).

Other operating expenses of TEUR 836,590 (previous year TEUR 804,604) are comprised as follows:

	2024 TEUR	2023 TEUR
Other operating expenses		
Management of land and buildings	201,848	189,565
Libraries	13,058	11,515
Other research expenses	151,776	134,472
of which:		
Travel costs	36,130	35,379
Conferences, advanced training	23,909	20,419
Publications, public relations	7,935	8,713
Other expenses for science and research purposes	83,801	69,961
Business requirements	113,687	108,268
Auditing and advisory costs	27,837	24,530
Further other expenses	51,682	42,141
Expenses from allocation to multi-year available funds	276,702	294,113

The **expenses for allocation to multi-year available funds** are attributable to the MPG excluding IPP and represent in relation to institutional funding and project funding the balance of subsidy-financed income and expenses in the statement of profit and loss. They are comprised as follows:

	TEUR
Expenses for allocation to multi-year available funds	
Institutional funding	
Basic funding	174,455
Special funding	-692
Project funding	87,339
Undisbursed funds for operations pursuant to §26 of the Federal Budget Ordinance (BHO) including MPI for Psychiatry	15,600
TOTAL	276,702

The **taxes on income and revenue** amount to TEUR 59 (previous year TEUR 114).

Transfers and subsidies granted

The MPG is authorized to transfer funding provided to it to various final recipients as a non-repayable subsidy.

Funding was transferred as follows in the reporting year:

	2024 TEUR	2023 TEUR
TRANSFERS AND SUBSIDIES GRANTED		
For institutional funding, MPG excluding IPP		
to institutions within Germany	8,297	8,986
to institutions abroad	33,837	26,759
For project funding, MPG excluding IPP		
in Germany	5,535	6,683
of which from special funding	2,400	2,557
abroad	2,602	2,947
For the transfer of personnel due to closures/partial closures, MPG excluding IPP	0	0
Transferred IPP subsidies	0	0
TOTAL	50,271	45,375
<i>for information purposes: subsidies granted to internal institutions</i>	<i>38,783</i>	<i>30,278</i>

The subsidies granted to internal institutions were consolidated in the annual financial statements.

Expense from addition to the extraordinary item (subsidized investments)

Expenses from addition to the extraordinary item to finance intangible and tangible fixed assets (TEUR 340,539, previous year TEUR 372,555) represent the subsidized investments in these assets. They correlate in their entirety with the additions in the reporting year in accordance with the statement of changes in fixed assets (TEUR 340,497). The difference consists, firstly, of the additions to the NÖV (TEUR 483). Secondly, expenses from the addition to the extraordinary item to finance intangible and tangible fixed assets include subsequent capitalizations of the current year at their book value (TEUR 525), which are presented openly in separate columns in the statement of changes in fixed assets.

Expenses from addition to the extraordinary item to finance financial assets and shares in spin-offs (TEUR 192, previous year TEUR 108) result from expenses for the acquisition of shares in spin-offs (TEUR 192).

5. Other disclosures

Contingent liabilities and other financial obligations

No risks existed from off-balance sheet transactions as defined by § 285 No. 3 HGB or contingent liabilities pursuant to § 251 HGB as of the balance sheet date.

Regarding the Max Planck Digital Library, obligations arise up to the amount of EUR 175.2 million in the period covered by the medium-term budgetary accounting (2025 to 2029) for the MPG-wide basic supply of software and online services as well as literature. The licence contracts required for this purpose are of different durations.

Other financial obligations of around EUR 240.9 million also result from the perspective of the medium-term budgetary accounting of the MPG from the pro rata funding of jointly maintained institutions or joint ventures during scientific collaborations. In particular, this relates the Max Planck Florida Institute for Neuroscience, the Deutsches Klimarechenzentrum GmbH, the Gesellschaft für wissenschaftliche Datenverarbeitung mbH Göttingen, the Institut de Radio Astronomie Millimétrique as well as the Large Binocular Telescope .

The MPG appoints its top scientists for life and undertakes as part of the appointment to provide its scientists with funds for their basic scientific equipment. The announced call for these funds will result in possible obligations of around EUR 166.0 million within the timeframe of the medium-term budgetary accounting.

As of 31 December 2024, total construction costs budgeted but not yet disbursed amount to around EUR 1,234.1 million for major construction projects already commenced by Institutes and facilities.

Order obligations aside from construction projects total around EUR 108.7 million as of 31 December 2024.

Employees

The MPG employed an average of 19,937 staff during the financial year:

	Number 2024	Number 2023
Scientists	6,482	6,407
Doctoral students with funding contracts	3,315	3,302
Non-scientific staff	8,684	8,519
Student and graduate assistants	1,456	1,462
EMPLOYEES (excluding trainees and interns)	19,937	19,690
<i>for information purposes: Scholarship holders</i>	<i>467</i>	<i>511</i>

Participations

The MPG holds shares in other companies or major international projects in order to exploit synergy effects for scientific assignments to the best possible long-term advantage.

As of 31 December 2024, the following shareholdings existed:

Name	Registered seat	Purpose	Share in the capital %	Book value as of 31.12.2024 EUR
SHARES IN AFFILIATED COMPANIES				
Max-Planck-Innovation GmbH	Munich	The company manages and exploits intangible invention assets owned by the Max Planck Society.	100.00	500,000.00
Minerva Stiftung Gesellschaft für die Forschung mbH	Munich	The purpose of the (non-profit) company is to fund science and research, on the one hand by providing financial support for research projects at home and abroad, and on the other by operating funding programmes, principally in Israel.	100.00	26,000.00
Max-Planck-Stiftung für Internationalen Frieden und Rechtsstaatlichkeit gemeinnützige GmbH	Heidelberg	The purpose of the company is the advancement of science and research, the international ethos of tolerance and the concept of international understanding, development cooperation, public and professional education as well as democracy as a political system.	100.00	25,000.00
Deutsches Klima-rechenzentrum GmbH	Hamburg	The object and purpose of the (non-profit) company is the promotion of basic research and applied research in climatology and the disciplines immediately related to climatology. The purpose is achieved in particular through the expansion and operation of a climate computing centre.	54.50	31,200.00
Max-Planck-Institut für Nachhaltige Materialien Gesellschaft mit beschränkter Haftung	Düsseldorf	The object of the company (non-profit) is freely and independently conducted scientific research, primarily basic research. This purpose is realized in particular by carrying out its own research projects in the field of complex materials.	100.00	26,000.00

Name	Registered seat	Purpose	Share in the capital %	Book value as of 31.12.2024 EUR
PARTICIPATIONS				
Gesellschaft für wissenschaftliche Datenverarbeitung mbH Göttingen	Göttingen	This (non-profit) company promotes science and research. It fulfils the function of a computing and competence centre for the MPG and a university computing centre for the University of Göttingen.	50.00	26,000.00
Max Planck Graduate Center mit der Johannes Gutenberg-Universität Mainz GmbH	Mainz	The object of the (non-profit) company is the advancement of science and research, in particular by means of interdisciplinary teaching and doctoral programmes for junior scientists.	50.00	12,500.00
Cyber Valley GmbH	Stuttgart	The object of the company is to strengthen the research, development, application and acceptance of methods and technologies in the field of intelligent systems.	49.00	12,319.12
Institut de Radio Astronomie Millimétrique	Grenoble/France	The object is the joint operation of two observation stations on Pico Veleta (30-metre telescope) in Spain and on the Plateau de Bure (NOEMA observatory with twelve 15-metre telescopes) in France as well as a science laboratory in Grenoble, France.	47.00	716.75
MPDL Services gGmbH	Munich	The object of the company is the (in-house) provision to public and non-profit clients, especially German scientific institutions, of access to scientific literature (access rights) and scientific publication services for the DEAL project of the Alliance of Scientific Organisations, in return for a fee to cover costs. This purpose is fulfilled, in particular, through the awarding and management of contracts (including contracts for the benefit of third parties) with publishers and other service providers.	31.25	33,250.00
EuResist Network GEIE	Rome/Italy	European Economic Interest Grouping, founded as part of the 7th EU research framework programme for the "CHAIN – Collaborative HIV and Anti-HIV Drug Resistance Network" project.	20.00	3,100.22
Health + Life Science Alliance Heidelberg Mannheim gGmbH	Heidelberg	In particular, the purpose of the company is to create a joint research hub for life sciences and medical research, to support the realization of top appointments of scientists and the recruitment of young talent for the region, the establishment and operation of joint high-tech platforms, the acquisition of third-party funds and the promotion of cross-institutional programs in research and teaching.	14.29	3,600.00
Wissenschaft im Dialog gGmbH	Berlin	The object of the company is to promote dialogue between science and society with special regard to the latest public forms of communication, to promote understanding between science, research and the public, information on the methods and processes of scientific research as well as to emphasize the mutual interactions and dependencies of science, business and society.	8.33	5,000.00
Schloss Dagstuhl – Leibniz Zentrum für Informatik Gesellschaft mit beschränkter Haftung	Wadern	As an international meeting point and research centre for computer science, the task of this (non-profit) company is to conduct scientific computer science conferences.	7.70	5,200.00
Cherenkov Telescope Array Observatory gemeinnützige GmbH	Heidelberg	The company is responsible for: <ul style="list-style-type: none"> – developing the planning and preparing the realization of the CTAO Facility as well as the development of the founding accord for the construction and Operation of the CTAO Facility – selecting and equipping the telescope locations – planning and development as well as construction and operation of prototype telescopes and related instruments and infrastructure for test purposes – preparation of programmes for scientific research conducted in the CTAO Facility. 	5.00	1,250.00

Name	Registered seat	Purpose	Share in the capital %	Book value as of 31.12.2024 EUR
LSI Pre-Seed-Fonds GmbH	Bonn	LSI PSF GmbH operates together with Life Science Inkubator GmbH & Co. KG (management company Life Science Inkubator GmbH is a wholly-owned subsidiary of Max-Planck Innovation GmbH) an incubator for researchers from German universities and research facilities interested in founding their own company.	3.76	550,000.00
FIZ Karlsruhe – Leibniz Institut für Informationsinfrastruktur GmbH	Eggenstein-Leopoldshafen	The task of this (non-profit) company is to provide science and research with scientific information, develop corresponding products and services in the field of scientific information infrastructure and to make them publicly accessible.	3.26	1,560.00
Futurium gGmbH (vormals Haus der Zukunft gGmbH)	Berlin	The company's purpose is to operate the Futurium as a location for presentations and dialog for science, research and development. Exhibitions and events are to make future-oriented scientific and technical developments of national and international significance visible, and present them for discussion.	1.00	250.00

No details are given of these companies' equity or their results in the last financial year due to their subordinate significance in accordance with §286 para. 3 sentence 1 No. 1 HGB.

The MPG refrains from preparing consolidated financial statements in the meaning of No. 14(1) of the Management Principles for the MPG (BewGr-MPG), as the participations reported under the balance sheet item "shares in affiliated companies" are of subordinate significance, both individually as well as together, for the net assets, financial position and results of operations of the MPG.

MPG Bodies in their tasks

The MPG Statutes specify the following bodies:

- the President,
- the Executive Committee,
- the Senate,
- the General Meeting,
- the Scientific Council and its Sections

The **President** represents the Max Planck Society, drafts the outlines of its science policy, and works to ensure trustful collaboration within the Max Planck Society. The President chairs the Senate, Executive Committee and General Meeting. In cases that cannot be deferred, the President may make decisions falling within these bodies' competency.

The **Executive Committee** advises the President and prepares resolutions for the Senate and the General Meeting. It prepares the overall budget and submits it to the Senate for adoption. It also prepares the annual report as well as the annual accounts for adoption by the Senate. Furthermore, through the President, it exercises a supervisory role over the Administrative Headquarters and possesses the decision-making power in all of the Society's matters that are not allocated to another body and that extend above and beyond current transactions to be managed by the Administrative Headquarters. Together with the Secretary General (the Secretary Generals), it forms the Management Board in the meaning of the law.

The **Senate** is an important decision-making body of the Max Planck Society. The Senate elects the President and other members of the Executive Committee and decides on the appointment of the Secretary General. It decides on the foundation and closure of Institutes and Departments, the appointment of Scientific Members and the by-laws of the Institutes. The Senate decides on the involvement of the Max Planck Society in other institutions and approves the overall budget; it also approves the annual report and presents it to the General Meeting. It adopts the annual accounts and decides on the admission of Supporting Members. The Senate can also pass resolutions on all matters of the Max Planck Society that the Statutes do not reserve for the General Meeting. The voting-entitled members of the Senate include both Elected Senators and Ex officio Members. The Senate's composition reflects the aim to draw on experience from all important areas of public life in important decisions. For this reason, the

Elected Senators – of whom there are a minimum of twelve and a maximum of 32 – include not only outstanding MPG scientists but also high-ranking representatives of the federal government and the federal states, important personalities from business enterprises and scientific organizations as well as other socially relevant groups.

The Senate is supported by three Senate Committees:

- The **Senate Committee for Research Planning** advises on questions of research policy and research planning.
- The **Audit Committee** reviews the lawfulness of budget implementation and the correctness of the Society's accounting, as well as the effectiveness of its risk and compliance management. It makes proposals to the General Meeting regarding the appointment of external auditors, determines the criteria and scope of the audit engagement and receives the external auditors' reports. It receives the annual report of the Internal Auditing Department and is authorized to prompt further audits.
- The task of the **Employment Committee** is to decide upon the reward of and upon the approval of ancillary activities undertaken by the President and upon the reward of and upon the approval of function-related ancillary activities undertaken by the other members of the Executive Committee. The Employment Committee is further tasked with deciding upon the reward of former Presidents in return for the performance of tasks for the Society.

The **General Meeting** (the meeting of its members) is the uppermost association body of the Max Planck Society. It decides on amendments to the Society's Statutes, elects the Senate members, receives the annual report, audits and approves the annual accounts, and grants approbation. The Society's members include its Scientific Members, Supporting Members, Ex officio Members, and Honorary Members.

The **Scientific Council** consists of Scientific Members and the heads of the Institutes and of research facilities equivalent to Institutes. It also comprises scientific staff elected by the Institutes to the Sections. The Emeritus Scientific Members and the External Scientific Members of the Institute may attend meetings as guests in an advisory capacity. The Scientific Council is divided into three Sections. The Sections' task is to discuss the Institutes' joint matters and prepare the Senate's scientific decisions through specialist recommendations.

Staff of the MPG governing bodies³

PRESIDENT

Patrick Cramer, Prof. Dr., München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Multidisziplinäre Naturwissenschaften, Göttingen

EXECUTIVE COMMITTEE

PRESIDENT – CHAIRPERSON

Patrick Cramer, Prof. Dr., München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Multidisziplinäre Naturwissenschaften, Göttingen

VICE PRESIDENTS

Asifa Akhtar, Dr., Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Immunbiologie und Epigenetik, Freiburg

Frank Appel, Dr., Königswinter, Vorsitzender des Aufsichtsrats der Deutschen Telekom AG, Bonn (seit 14. Juni 2024)

Christian Doeller, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kognitions- und Neurowissenschaften, Leipzig

Claudia Felser, Prof. Dr., Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Chemische Physik fester Stoffe, Dresden

Sibylle Günter, Prof. Dr., Wissenschaftliches Mitglied und Wissenschaftliche Direktorin des Max-Planck-Instituts für Plasmaphysik, Garching

TREASURER

Ralf P. Thomas, Prof. Dr., Mitglied des Vorstands und Chief Financial Officer der Siemens AG, München

OTHER MEMBERS

Frank Appel, Dr., Königswinter, Vorsitzender des Aufsichtsrats der Deutschen Telekom AG, Bonn (bis 13. Juni 2024)

Renate Köcher, Prof. Dr., Geschäftsführerin des Instituts für Demoskopie Allensbach, Gesellschaft zum Studium der öffentlichen Meinung mbH, Allensbach

Nicola Leibinger-Kammüller, Dr., Vorsitzende des Vorstands und geschäftsführende Gesellschafterin der TRUMPF SE + Co. KG, Ditzingen

MANAGEMENT BOARD

Together with the Secretary General **Dr. Simone Schwanitz**, Munich, the Board of Directors forms the Executive Committee within the meaning of the law.

SENATE

CHAIRPERSON

Patrick Cramer, Prof. Dr., Präsident der Max-Planck-Gesellschaft, München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Multidisziplinäre Naturwissenschaften, Göttingen

ELECTED SENATORS

Asifa Akhtar, Dr., Vizepräsidentin der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Immunbiologie und Epigenetik, Freiburg

Frank Appel, Dr., Königswinter, Vizepräsident der Max-Planck-Gesellschaft, Vorsitzender des Aufsichtsrats der Deutschen Telekom AG, Bonn

Simone Bagel-Trah, Dr., Vorsitzende des Aufsichtsrats und des Gesellschafterausschusses der Henkel AG & Co. KGaA, Düsseldorf

Heinrich Bedford-Strohm, Prof. Dr., Mirow, Vorsitzender des Zentralausschusses des Ökumenischen Rats der Kirchen (ÖRK), Genf, Schweiz

Christiane Benner, Erste Vorsitzende des Vorstands der IG Metall, Frankfurt/Main

Antje Boetius, Prof. Dr., Auswärtiges Wissenschaftliches Mitglied des Max-Planck-Instituts für marine Mikrobiologie, Bremen, Direktorin des Alfred-Wegener-Instituts – Helmholtz-Zentrum für Polar- und Meeresforschung, Bremerhaven

Tanja Brühl, Prof. Dr., Präsidentin der Technischen Universität Darmstadt, Darmstadt

Alon Chen, Prof. Ph. D., Auswärtiges Wissenschaftliches Mitglied des Max-Planck-Instituts für Psychiatrie, München, Präsident des Weizmann Institute of Science, Rehovot, Israel

Anna Christmann, Dr., MdB, Bundestagsfraktion Bündnis 90/ Die Grünen, Berlin

³The dates in brackets show the date of leaving (until/bis) or joining (since/seit) the respective governing body.

Christian Doeller, Prof. Dr., Vizepräsident der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kognitions- und Neurowissenschaften, Leipzig

Malu Dreyer, Ministerpräsidentin a. D. des Landes Rheinland-Pfalz, Mainz

Claudia Felser, Prof. Dr., Vizepräsidentin der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Chemische Physik fester Stoffe, Dresden

Sibylle Günter, Prof. Dr., Vizepräsidentin der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Wissenschaftliche Direktorin des Max-Planck-Instituts für Plasmaphysik, Garching

Franz-Ulrich Hartl, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Biochemie, Martinsried

Edith Heard, Prof. Ph. D., FRS, Generaldirektorin des European Molecular Biology Laboratory, Heidelberg

Stefan W. Hell, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Multidisziplinäre Naturwissenschaften, Göttingen, und Direktor am Max-Planck-Institut für medizinische Forschung, Heidelberg

Michael Kaschke, Prof. Dr., Präsident des Stifterverbandes für die Deutsche Wissenschaft e. V., Essen

Renate Köcher, Prof. Dr., Mitglied des Verwaltungsrats der Max-Planck-Gesellschaft, Geschäftsführerin des Instituts für Demoskopie Allensbach, Gesellschaft zum Studium der öffentlichen Meinung mbH, Allensbach

Michael Kretschmer, Ministerpräsident des Freistaates Sachsen, Dresden

Joachim Kreuzburg, Dr., Chief Executive Officer der Sartorius AG, Göttingen

Heyo K. Kroemer, Prof. Dr., Vorstandsvorsitzender der Charité – Universitätsmedizin Berlin, Berlin

Sabine Kunst, Prof. Dr.-Ing. Dr., Vorsitzende des Vorstands der Joachim Herz Stiftung, Hamburg

Nicola Leibinger-Kammüller, Dr., Mitglied des Verwaltungsrats der Max-Planck-Gesellschaft, Vorsitzende des Vorstands und geschäftsführende Gesellschafterin der TRUMPF SE + Co. KG, Ditzingen

Bettina Limperg, Präsidentin des Bundesgerichtshofs, Karlsruhe

Melanie Maas-Brunner, Dr., ehem. Mitglied des Vorstands und Chief Technology Officer der BASF SE, Ludwigshafen (bis 31. Dezember 2024)

Mai Thi Nguyen-Kim, Dr., Wissenschaftsjournalistin, Köln

Sabine Nikolaus, Dr., Vorsitzende der Geschäftsführung der Boehringer Ingelheim Deutschland GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein

Wolfgang Schön, Prof. Dr. Dr. h. c., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Steuerrecht und Öffentliche Finanzen, München

Peter Seeberger, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Potsdam

Andreas Sentker, Geschäftsführender Redakteur DIE ZEIT, Hamburg

Ralf P. Thomas, Prof. Dr., Schatzmeister der Max-Planck-Gesellschaft, Mitglied des Vorstands und Chief Financial Officer der Siemens AG, München

Joachim Wenning, Dr., Vorsitzender des Vorstands der Münchener Rückversicherungs-Gesellschaft AG, München

EX OFFICIO MEMBERS

Markus Blume, Bayerischer Staatsminister für Wissenschaft und Kunst, München, als Vertreter der Länder (seit 26. April 2024)

Nils Brose, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Multidisziplinäre Naturwissenschaften, Göttingen, als Vorsitzender der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (seit 14. Juni 2024)

Christoph Brumann, Prof. Dr., Forschungsgruppenleiter am Max-Planck-Institut für ethnologische Forschung, Halle (Saale), als Vertreter der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Andreas Dressel, Dr., Präses der Finanzbehörde der Freien und Hansestadt Hamburg, als Vertreter der Länder

Gloria von Eilpe, als Vorsitzende des Gesamtbetriebsrates der Max-Planck-Gesellschaft, München

Stephan Ertner, als Staatssekretär im Bundesministerium für Bildung und Forschung, Berlin (seit 18. Dezember 2024)

Michael Kramer, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Radioastronomie, Bonn, als Vorsitzender der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Gabriele Lohmann, Priv.-Doz. Dr., Gruppenleiterin am Max-Planck-Institut für biologische Kybernetik, Tübingen, als Vertreterin der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Mikko Myrskylä, Prof. Ph. D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für demografische Forschung, Rostock, als Vorsitzender des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Manja Schüle, Dr., Ministerin für Wissenschaft, Forschung und Kultur des Landes Brandenburg, Potsdam, als Vertreterin der Länder

Simone Schwanitz, Dr., als Generalsekretärin der Max-Planck-Gesellschaft, München

Bettina Stark-Watzinger, MdB, Bundesministerin für Bildung und Forschung, Berlin, als Vertreterin des Bundes (bis 7. November 2024)

Heiko Thoms, Staatssekretär im Bundesministerium der Finanzen, Berlin (seit 6. März 2024)

Udo von Toussaint, Priv.-Doz. Dr., Leiter einer Arbeitsgruppe am Max-Planck-Institut für Plasmaphysik, Garching, als Vertreter der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Arno Villringer, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kognitions- und Neurowissenschaften, Leipzig, als Vorsitzender der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Martin Vingron, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Genetik, Berlin, als Vorsitzender der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 13. Juni 2024)

SENATORS WITHOUT VOTING RIGHTS

HONORARY MEMBERS

Peter Gruss, Prof. Dr., Göttingen, Präsident der Max-Planck-Gesellschaft von 2002 bis 2014, Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für Multidisziplinäre Naturwissenschaften

Reinhard Pöllath, Prof. Dr., Rechtsanwalt, P+P Pöllath + Partners Rechtsanwälte und Steuerberater mbB, München

Martin Stratmann, Prof. Dr., Düsseldorf, Präsident der Max-Planck-Gesellschaft von 2014 bis 2023, Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für Nachhaltige Materialien GmbH

HONORARY SENATORS

Stefan von Holtzbrinck, Dr., Vorsitzender der Geschäftsführung der Holtzbrinck Publishing Group, Stuttgart

Ernst-Joachim Mestmäcker, Prof. Dr. Dr. h. c., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für ausländisches und internationales Privatrecht, Hamburg (bis 22. April 2024)

Christiane Nüsslein-Volhard, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für Biologie Tübingen, Tübingen

PERMANENT GUESTS OF THE SENATE

Katja Becker, Prof. Dr., als Präsidentin der Deutschen Forschungsgemeinschaft, Bonn

Martina Brockmeier, Prof. Dr., als Präsidentin der Leibniz-Gemeinschaft, Berlin

Hagen Duenbostel, Dr., Aufsichtsratsvorsitzender der KWS SAAT SE & Co. KGaA, Einbeck, als Vorsitzender des Prüfungsausschusses des Senats

Holger Hanselka, Prof. Dr.-Ing., als Präsident der Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V., München

Gerald Haug, Prof. (ETHZ) Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Chemie (Otto-Hahn-Institut), Mainz, Deutsche Akademie der Naturforscher Leopoldina, Halle (Saale), als Präsident der Nationalen Akademie der Wissenschaften

Michael Kaschke⁴, Prof. Dr., als Präsident des Stifterverbandes für die Deutsche Wissenschaft e. V., Essen

⁴ Prof. Kaschke ist außerdem Wahlsenator der Max-Planck-Gesellschaft.

Petra Olschowski, MdL, Ministerin für Wissenschaft, Forschung und Kunst des Landes Baden-Württemberg, Stuttgart, als Vertreterin der Länder

Walter Rosenthal, Prof. Dr., als Präsident der Hochschulrektorenkonferenz, Bonn

Wolfgang Tiefensee, Thüringer Minister für Wirtschaft, Wissenschaft und Digitale Gesellschaft, Erfurt, als Vertreter der Länder (bis 13. Dezember 2024)

Wolfgang Wick, Prof. Dr., als Vorsitzender des Wissenschaftsrates, Köln

Otmar D. Wiestler, Prof. Dr. Dr. h. c., als Präsident der Hermann von Helmholtz-Gemeinschaft Deutscher Forschungszentren e. V., Berlin

SENATE COMMITTEES

SENATE COMMITTEE FOR RESEARCH PLANNING

The Senate Committee for Research Planning was suspended in 2023. No meetings were held in 2024.

AUDIT COMMITTEE OF THE SENATE

Tanja Brühl, Prof. Dr., Präsidentin der Technischen Universität Darmstadt, Darmstadt, als Wahlsenatorin der Max-Planck-Gesellschaft

Hagen Duenbostel, Dr., Aufsichtsratsvorsitzender der KWS SAAT SE & Co. KGaA, Einbeck, als Förderndes Mitglied der Max-Planck-Gesellschaft

Sabine Nikolaus, Dr., Vorsitzende der Geschäftsführung der Boehringer Ingelheim Deutschland GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, als Wahlsenatorin der Max-Planck-Gesellschaft

EMPLOYMENT COMMITTEE OF THE SENATE

Andreas Barner, Prof. Dr. Dr., ehem. Mitglied des Gesellschafterausschusses der C. H. Boehringer Sohn AG & Co. KG, Ingelheim am Rhein, als Förderndes Mitglied der Max-Planck-Gesellschaft

Heinrich Bedford-Strohm, Prof. Dr., Mirow, Vorsitzender des Zentralausschusses des Ökumenischen Rats der Kirchen (ÖRK), Genf, Schweiz, als Wahlsenator der Max-Planck-Gesellschaft

Joachim Kreuzburg, Dr., Chief Executive Officer der Sartorius AG, Göttingen, als Wahlsenator der Max-Planck-Gesellschaft

GENERAL MEETING

CHAIRPERSON

Patrick Cramer, Prof. Dr., Präsident der Max-Planck-Gesellschaft, München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Multidisziplinäre Naturwissenschaften, Göttingen

MEMBERS

Die Hauptversammlung besteht aus den Mitgliedern der Gesellschaft. Dies sind: Fördernde Mitglieder, Wissenschaftliche Mitglieder, Mitglieder von Amts wegen und Ehrenmitglieder.

SCIENTIFIC COUNCIL

CHAIRPERSON

Mikko Myrskylä, Prof. Ph. D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für demografische Forschung, Rostock

VICE CHAIRPERSON

Jens Brüning, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Stoffwechselforschung, Köln

BIOLOGY & MEDICINE SECTION

CHAIRPERSON

Martin Vingron, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Genetik, Berlin (bis 13. Juni 2024)

Nils Brose, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Multidisziplinäre Naturwissenschaften, Göttingen (seit 14. Juni 2024)

VICE CHAIRPERSON

Nils Brose, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Multidisziplinäre Naturwissenschaften, Göttingen (bis 13. Juni 2024)

Martin Vingron, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Genetik, Berlin (seit 14. Juni 2024)

MEDIATORS

Rudolf I. Amann, Prof. Dr., Wissenschaftliches Mitglied des Max-Planck-Instituts für marine Mikrobiologie, Bremen

Regine Kahmann, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für terrestrische Mikrobiologie, Marburg (bis 13. Juni 2024)

Elisabeth Knust, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für molekulare Zellbiologie und Genetik, Dresden (seit 14. Juni 2024)

Daniel Piechowski, Dr., wissenschaftlicher Mitarbeiter des Max-Planck-Instituts für Verhaltensbiologie, Radolfzell

CHEMISTRY, PHYSICS & TECHNOLOGY SECTION

CHAIRPERSON

Michael Kramer, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Radioastronomie, Bonn

VICE CHAIRPERSON

Peter Druschel, Prof. Ph. D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Softwaresysteme, Saarbrücken (bis 13. Juni 2024)

Florian Marquardt, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für die Physik des Lichts, Erlangen (seit 14. Juni 2024)

MEDIATORS

Gerhard Dehm, Univ.-Prof. Dipl.-Ing. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Nachhaltige Materialien GmbH, Düsseldorf

Alexander Paarmann, Ph. D., wissenschaftlicher Mitarbeiter des Fritz-Haber-Instituts der Max-Planck-Gesellschaft, Berlin

Gisela Schütz, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für Intelligente Systeme, Stuttgart

HUMAN SCIENCES SECTION

CHAIRPERSON

Arno Villringer, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kognitions- und Neurowissenschaften, Leipzig

VICE CHAIRPERSON

Ulrich Becker, Prof. Dr. LL. M. (EHI), Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Sozialrecht und Sozialpolitik, München (bis 13. Juni 2024)

Stefan Vogenauer, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Rechtsgeschichte und Rechtstheorie, Frankfurt am Main (seit 14. Juni 2024)

MEDIATORS

Marie-Claire Foblets, Prof., Ph. D., Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für ethnologische Forschung, Halle (Saale)

Wolfgang Klein, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für Psycholinguistik, Nijmegen, Niederlande

Johannes Röhl, Dr., wissenschaftlicher Mitarbeiter der Bibliotheca Hertziana – Max-Planck-Institut für Kunstgeschichte, Rom, Italien (bis 13. Juni 2024)

Daniela Sammler, Priv.-Doz. Dr., wissenschaftliche Mitarbeiterin des Max-Planck-Instituts für empirische Ästhetik, Frankfurt am Main (seit 14. Juni 2024)

Additional information

Total emoluments for the President, Vice President and Secretary General for their work on the Management Board and Executive Committee amounted to TEUR 600 for the calendar year 2024. Total emoluments for former members of the Management Board or Executive Committee (Civil Servant-type pensions and benefits for surviving dependants) amounted to TEUR 578. Provisions amounting to TEUR 9,384 exist for pension obligations to former members of the Management Board or Executive Committee. The Treasurer and other members of the Executive Committee did not receive any emoluments for their work on the Management Board and Executive Committee. Members of the Senate also received no emoluments for their work in the Senate.

The total fee for the auditor in the 2024 financial year amounted to TEUR 232. This related exclusively to work performed for the auditing of the annual financial statements.

No transactions of any material significance to the MPG were realized on non-standard terms with affiliated companies or persons.

The MPG holds all shares in the special securities assets fund DeAM-Fonds PMF 1 ISIN DE0008498080. The fund consists of two segments, "DBA" and "Others". Around 62% of the securities investments are actively managed in the DBA segment by a manager. The other securities investments (38%) in the Others segment are distributed across institutional funds in a diversified portfolio in accordance with the advisory support of an Investment Advisory Board. All securities assets are allocated in accordance with defined investment guidelines paying special attention to the criteria of risk, return, liquidity and sustainability of investments. As of 31 December 2024, the market value stood at EUR 181.62 million. The difference between this and the book value (EUR 141.33 million) amounted to EUR 40.29 million. No write-downs were required. The income generated in the 2024 reporting year from the special fund amounted to EUR 3.20 million. No restrictions of any legal or actual kind exist with regard to the redemption of shares.

In addition, the MPG holds all shares in the special securities assets DeAM-Fonds caesar 1 ISIN DE000DWS5099, which was launched on 21 February 2022. The fund consists of the two segments "DBA 2" and "Others 2". About 50% of the securities investments in the segment DBA 2 are actively managed by one manager. The securities investments in the Others 2 segment (50%) are also actively managed by another manager. In addition, there are fund shares in direct investments in two public funds with a market value of EUR 57.64 million and EUR 31.63 million, as well as in a money market ETF with a market value of EUR 12.77 million as of 31 December 2024. All securities assets are allocated in accordance with defined investment guidelines paying special attention to the criteria of risk, return, liquidity and sustainability of the investments. In total, the market value of the caesar assets thus amounted to EUR 254.94 million as of 31 December 2024. The difference between this and the book value (EUR 243.25 million) amounted to EUR 11.69 million. Write-downs were not required. No distribution was made in the reporting year. No restrictions of any legal or actual kind exist with regard to the redemption of shares.

Events of particular significance after the end of the financial year

No events of particular significance for the net assets, financial position and results of operations occurred after the end of fiscal year 2024.

Berlin, 28 April 2025

**Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V., Berlin
– The Executive Committee –**

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

Annex to the notes to the financial statements

STATEMENT OF CHANGES IN FIXED ASSETS AS OF 31 DECEMBER 2024

COSTS OF PURCHASING OR MANUFACTURING

	Balance on 01.01.2024 EUR	Addition 2024 EUR	Subsequent capitalization/ Transfer as of 1.01.2024 EUR	Disposal 2024 EUR	Rebooking 2024 EUR	Balance on 31.12.2024 EUR
I. INTANGIBLE ASSETS						
1. Purchased concessions, industrial property rights and similar rights and assets, as well as licences to such rights and assets	80,086,127.13	4,579,195.78	13,902.96	-5,289,857.41	-276,107.22	79,113,261.24
2. Prepayments made	910,633.65	885,454.20	0.00	0.00	-282,070.92	1,514,016.93
	80,996,760.78	5,464,649.98	13,902.96	-5,289,857.41	-558,178.14	80,627,278.17
II. TANGIBLE FIXED ASSETS						
1. Land, rights equivalent to land, and buildings including buildings on third-party land	2,920,072,790.22	22,179,820.90	0.00	-1,286,763.52	129,829,281.38	3,070,795,128.98
2. Technical plant and machinery	3,385,647,226.68	101,931,142.26	1,306,111.93	-52,636,732.27	57,348,728.20	3,493,596,476.80
3. Other plant, operating and office equipment	1,226,810,853.58	78,001,434.69	2,071,019.22	-26,901,941.43	9,264,346.48	1,289,245,712.54
4. Prepayments made and plant under construction	357,522,753.85	132,919,918.55	0.00	-2,881,204.18	-195,884,177.92	291,677,290.30
	7,890,053,624.33	335,032,316.40	3,377,131.15	-83,706,641.40	558,178.14	8,145,314,608.62
III. FINANCIAL ASSETS						
1. Shares in affiliated companies	608,200.00	0.00	0.00	0.00	0.00	608,200.00
2. Participations	667,246.09	0.00	0.00	-12,500.00	0.00	654,746.09
3. Investment securities	408,898,616.47	52,090,870.70	0.00	-61,412,294.31	0.00	399,577,192.86
4. Other loans and shares	2,937,921.29	1,281,400.00	0.00	-785,867.74	0.00	3,433,453.55
	413,111,983.85	53,372,270.70	0.00	-62,210,662.05	0.00	404,273,592.50
TOTAL	8,384,162,368.96	393,869,237.08	3,391,034.11	-151,207,160.86	0.00	8,630,215,479.29

DEPRECIATION AND AMORTIZATION							BOOK VALUES		
Accumulated 01.01.2024 EUR	Financial year 2024 EUR	to subsequent capitalization/ Transfer as of 1.01.2024 EUR	to disposal 2024 EUR	to rebooking 2024 EUR	Write-up 2024 EUR	Accumulated 31.12.2024 EUR	Balance on 31.12.2024 EUR	Balance on 01.01.2024 EUR	
-72,696,294.25	-5,424,841.30	-8,064.56	5,288,816.41	222,699.27	0.00	-72,617,684.43	6,495,576.81	7,389,832.88	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,514,016.93	910,633.65	
-72,696,294.25	-5,424,841.30	-8,064.56	5,288,816.41	222,699.27	0.00	-72,617,684.43	8,009,593.74	8,300,466.53	
-1,620,654,311.02	-70,307,078.07	0.00	1,238,526.52	-926.50	0.00	-1,689,723,789.07	1,381,071,339.91	1,299,418,479.20	
-2,920,215,435.95	-166,764,660.22	-1,145,891.93	51,964,104.87	-310,618.12	40,175.05	-3,036,432,326.30	457,164,150.50	465,431,790.73	
-1,052,375,642.96	-81,981,890.70	-1,711,971.22	26,506,969.32	88,845.35	590.45	-1,109,473,099.76	179,772,612.78	174,435,210.62	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	291,677,290.30	357,522,753.85	
-5,593,245,389.93	-319,053,628.99	-2,857,863.15	79,709,600.71	-222,699.27	40,765.50	-5,835,629,215.13	2,309,685,393.49	2,296,808,234.40	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	608,200.00	608,200.00	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	654,746.09	667,246.09	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	399,577,192.86	408,898,616.47	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	3,433,453.55	2,937,921.29	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	404,273,592.50	413,111,983.85	
-5,665,941,684.18	-324,478,470.29	-2,865,927.71	84,998,417.12	0.00	40,765.50	-5,908,246,899.56	2,721,968,579.73	2,718,220,684.78	

INDEPENDENT AUDITORS REPORT

To the Max Planck Society for the Advancement of Science
(Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.), Berlin

Audit opinions

We have audited the annual financial statements of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin, comprising the balance sheet as at 31 December 2024, the statement of profit and loss for the financial year from 1 January to 31 December 2024, and the notes to the annual financial statements, including the presentation of the accounting policies. In addition, we have audited the management report of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin, for the financial year from 1 January to 31 December 2024.

In our opinion, on the basis of the knowledge obtained in the audit,

- the enclosed annual financial statements comply in all significant respects with the German commercial law regulations applicable to corporations and gives a true and fair view pursuant to the German principles of proper accounting of the net assets and financial position of the association as of 31 December 2024 as well as of the results of operations for the financial year from 1 January to 31 December 2024, and
- the enclosed management report as a whole provides a suitable view of the association's position. In all significant respects, the management report is consistent with the annual financial statements, complies with German statutory regulations and suitably presents the opportunities and risks of future development.

Pursuant to §322 para. 3 sentence 1 German Commercial Code (HGB), we declare that our audit has not led to reservations against the correctness of the annual financial statements and of the management report.

Basis for the audit opinions

We conducted our audit of the annual financial statements and of the management report in accordance with §317 HGB and in compliance with German generally accepted standards for the audit of financial statements promulgated by the Institute of Public Auditors in Germany (IDW). Our responsibility under these regulations and principles are further described in "The auditor's responsibility for the audit of the annual financial statements and the management report" section of our auditor's report. We are independent of the association in accordance with the German commercial law and professional law regulations and we have fulfilled our other German professional obligations in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions on the annual financial statements and on the management report.

Responsibility of the Executive Committee and of the Audit Committee for the annual financial statements and the management report

The Executive Committee is responsible for the preparation of the annual financial statements that comply, in all significant respects, with the German commercial law regulations applicable to corporations, and for the annual financial statements that give a true and fair view of the net assets, financial position and results of operations of the association in accordance with German principles of proper accounting. Furthermore, the Executive Committee is responsible for such internal controls as they, in accordance with German principles of proper accounting, have determined necessary to permit the preparation of annual financial statements that are free from material misstatements, whether due to fraud or error (i. e. accounting manipulations and asset damages).

In preparing the annual financial statements, the Executive Committee is responsible for assessing the association's ability to continue as a going concern. Moreover, the Executive Committee has the responsibility for disclosing, as applicable, matters related to going concern. In addition, it is responsible for accounting based on the going concern accounting principle, unless actual or legal circumstances preclude this.

The Executive Committee is also responsible for the preparation of the management report, that as a whole provides a suitable view of the association's position and which is consistent with the annual financial statements in all significant respects, complies with German statutory regulations and suitably presents the opportunities and risks of future development. The Executive Committee is furthermore responsible for the provisions and measures (systems) that it deems necessary to enable the preparation of a management report in accordance with the applicable German statutory regulations and to be able to provide sufficient appropriate evidence for the statements contained in the management report.

The Audit Committee is responsible for monitoring the association's accounting process of preparing the annual financial statements and the management report.

The auditor's responsibility for the audit of the annual financial statements and the management report

It is our objective to obtain sufficient certainty whether the annual financial statements in its entirety are free from material misstatements, whether due to fraud or error, and whether the management report as a whole provides a suitable view of the association's position and, in all significant respects, is consistent with the annual financial statements and the knowledge obtained in the audit, complies with the German legal requirements and adequately presents the opportunities and risks of future development, as well as to issue an auditor's report that includes our audit opinions on the annual financial statements and on the management report.

Sufficient certainty is a high level of certainty, but it is not a guarantee that an audit conducted in accordance with §317 HGB and in compliance with German principles of proper auditing promulgated by the Institute of Public Auditors in Germany (IDW) will always detect a material misstatement. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial statements and this management report.

Throughout the audit, we exercise professional judgement and maintain a critical basic attitude. In addition,

- we identify and assess the risks of material misstatements, whether due to fraud or error, in the annual financial statements and in the management report, plan and perform audit procedures responsive to those risks, and gain audit evidence that is sufficient and appropriate to provide a basis for our audit opinions. The risk that a material misstatement resulting from fraudulent acts may not be detected is higher than the risk that a material misstatement resulting from errors will not be detected, as fraudulent acts may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal controls.
- we gain an understanding of the internal controls relevant for the audit of the annual financial statements and the provisions and measures relevant for the audit of the management report in order to plan audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an audit opinion on the effectiveness of of the association's internal controls or these arrangements and measures.

- we evaluate the appropriateness of the accounting methods used by the Executive Committee and the justifiability of the estimates and related disclosures presented by the Executive Committee.
- we conclude on the appropriateness of the Executive Committee's use of the going concern accounting principle and, based on the audit evidence obtained, whether material uncertainty exists related to events or circumstances that could raise significant doubts on the association's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the relevant disclosures in the annual financial statements and in the management report or, if such disclosures are inadequate, to modify our respective audit opinion. We draw our conclusions on the basis of the audit evidence obtained up to the date of our auditor's report. However, future events or circumstances may cause the association to cease to be able to continue as a going concern.
- we evaluate the presentation, structure and content of the annual financial statements as a whole, including the disclosures, and whether the annual financial statements present the underlying business transactions and events in a manner that the annual financial statements give a true and fair view of the net assets, financial position and results of operations of the association in accordance with German principles of proper accounting.
- we evaluate the management report's consistency with the annual financial statements, its compliance with the German law, and the view of the association's position it provides.
- we perform audit procedures on the forward-looking statements presented by the Executive Committee in the management report. On the basis of sufficient appropriate audit evidence we review, in particular, the significant assumptions used by the Executive Committee as a basis for the forward-looking statements, and evaluate the proper derivation of the forward-looking statements from these assumptions. We do not express a separate audit opinion on the forward-looking statements and on the underlying assumptions. There is a substantial unavoidable risk that future events will differ materially from the forward-looking statements.

We communicate with those charged with governance, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

Munich, 28 April 2025

Deloitte GmbH

Wirtschaftsprüfungsgesellschaft

Anton Schreitt
Wirtschaftsprüfer
(German Public Auditor)

Markus Kraus
Wirtschaftsprüfer
(German Public Auditor)



